Recent news primarily covers broader market and sector developments; notable company-specific news includes the 2025 asset acquisition and strategic transition announcements.

• The Cannaisseur Group, Inc. closed a $35 million asset acquisition in August 2025, adding AgTech and sensor technology assets, resolving shell risk designation, and establishing a path toward OTCQB and potential NASDAQ candidacy [N1].
• In April 2025, TCRG executed a letter of intent to acquire $35 million in AgTech and sensor technology assets, initiating a strategic transition [N1].
• The company formed a transition team in April 2025 to support the upcoming strategic transaction and operational integration [N1].

The company has expanded its asset base through a $35 million acquisition, adding AgTech and sensor technology assets that diversify its operations beyond hemp-derived CBD products. This strategic move resolves prior shell risk issues and positions the company for uplisting to OTCQB and potential NASDAQ candidacy, which could enhance liquidity and institutional interest. Leveraging Atlanta CBD's established retail and online presence, TCRG aims to capitalize on growing consumer demand for health and wellness products, including functional nutrition and hydration solutions. The integration of technology into wellness products presents opportunities for market growth and product innovation.

TCRG operates in a highly competitive and regulated market with significant operational and financial challenges. The company reported no revenue and a net loss in the latest quarter, with limited liquidity and high current liabilities. Regulatory uncertainty around hemp-derived CBD products, including FDA oversight and state-level regulations, creates compliance risks. The company's reliance on third-party suppliers and contract manufacturers exposes it to supply chain disruptions and cost pressures. Management conflicts of interest between TCRG and Atlanta CBD may affect governance. The company's stock is thinly traded on OTC Pink with low market visibility and high volatility, and there is no assurance of successful uplisting or sustained market acceptance of its products.

Cannaisseur Group's moat is limited given its early-stage status, limited operating history, and reliance on third-party suppliers and contract manufacturers. Its 51% ownership and operational control of Atlanta CBD provide some vertical integration in the hemp and wellness product supply chain. The recent acquisition of AgTech and sensor technology assets diversifies its asset base and operational capabilities, potentially creating synergies in sustainable agriculture and industrial automation. However, the company faces strong competition from established players in the health and wellness and functional beverage markets, and regulatory uncertainties around hemp-derived CBD products pose ongoing challenges. The lack of patents or trademarks and limited scale further constrain its competitive advantages.

• Regulatory Uncertainty: The company faces ongoing regulatory risks related to hemp-derived CBD products, including FDA regulatory authority and evolving state laws, which may impact product marketing and sales.
• Financial and Liquidity Risks: As of June 30, 2026, the company reported no revenue, a net loss, limited cash, and high current liabilities, indicating liquidity constraints and the need for additional capital.
• Operational Risks: Dependence on third-party suppliers and contract manufacturers for product development and fulfillment exposes the company to supply chain disruptions and cost increases.
• Competitive Risks: The health and wellness market is highly competitive with established major players, which may limit the company's ability to gain market share and achieve revenue growth.
• Governance and Conflict of Interest: Management of TCRG also runs Atlanta CBD, with conflict-of-interest agreements in place; however, these do not guarantee prioritization of TCRG's interests over Atlanta CBD's.
• Market and Trading Risks: The company's common stock is thinly traded on OTC Pink with high volatility and limited market visibility, which may affect liquidity and investor interest.
• Insurance and Legal Risks: The company currently lacks directors and officers liability insurance, which may expose it to financial and reputational risks from litigation.
• Cybersecurity Risks: The company collects and retains sensitive data and faces cybersecurity threats that could disrupt operations and harm its reputation.

• Cannaisseur Group Inc. (TCRG) was established in December 2020 and is a Delaware corporation.
• The company owns a 51% interest in Atlanta CBD Inc. (d/b/a Inno Medicinals), which engages in hemp cultivation, extraction, manufacturing, distribution, and retail sales of CBD and health and wellness products.
• TCRG manages and operates Atlanta CBD's business on a day-to-day basis and is entitled to 51% of Atlanta CBD's net profits.
• Atlanta CBD operates retail hemp stores and sells products online via https://innomedicinals.com, with sales limited to legal jurisdictions and customers aged 18 or older.
• TCRG has transitioned from a hemp business to a broader health and wellness company focusing on CBD-related and wellness products.
• The company uses commercial suppliers and contract manufacturers for product research, development, formulation, quality testing, production, and packaging, leveraging Atlanta CBD's supplier relationships.
• Sales channels include online distribution and the INNO Medicinals website, aiming to build an audience before entering retail locations.
• The company targets products addressing consumer wellness goals, including functional nutrition and hydration solutions, aligning with growing market demand.
• TCRG completed a $35 million asset acquisition in August 2025, adding AgTech and sensor technology assets, including real estate, equipment, IP for soy processing, human nutrition, agricultural manufacturing, and sensor systems applicable to agriculture, industrial, and automotive settings.
• This acquisition resolved the company's shell risk designation and established a path toward OTCQB listing and potential NASDAQ candidacy.
• The company issued convertible preferred equity and assumed approximately $500,000 in debt as part of the acquisition, with legacy shareholders retaining at least 6.5% of post-transaction equity.
• TCRG is currently delinquent in periodic disclosures with OTC Markets but intends to bring filings current and pursue OTCQB uplisting.
• As of June 30, 2026, the company reported cash and equivalents of $41,000 and current liabilities of $338,278, resulting in low liquidity ratios.
• The company reported zero revenue and a net loss of $94,889 for the quarter ended June 30, 2026.
• TCRG has three full-time employees and holds no patents or trademarks currently.
• The company is subject to FDA regulation under the Federal Food, Drug, and Cosmetic Act for its health and wellness products.
• The company faces competition from major health and wellness and functional beverage companies such as Nestlé, Danone, PepsiCo, and others.
• Management includes Floretta Gogo (President and CEO) and Xavier Carter (CFO), who also run Atlanta CBD's operations.
• There is a conflict-of-interest agreement in place between TCRG and Atlanta CBD management to prevent undue influence, though it cannot guarantee prioritization of TCRG interests over Atlanta CBD.
• The company plans to finance growth through equity and private placements to acquire assets and expand its health and wellness business.
• TCRG's common stock is quoted on the OTC Pink market and is thinly traded with high volatility and limited market visibility.
• The company does not anticipate paying dividends in the foreseeable future and may issue additional shares causing dilution.
• The company faces risks including regulatory uncertainty around hemp-derived CBD products, supply chain disruptions, competition, and operational challenges.
• The company is monitoring USDA rulemaking on hemp cultivation and FDA regulatory processes regarding CBD products.
• The company has committed resources to develop and market new products but faces uncertainty in market acceptance and competition.
• The company has no directors and officers liability insurance currently but intends to seek coverage.
• The company is exposed to cybersecurity risks and data protection challenges that could impact operations and reputation.